These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2957328)

  • 1. Chronic beta 1-blockade and control of left ventricular hypertrophy in hypertension.
    Fogari R; Zoppi A; Poletti L; Tettamanti F; Orlandi C
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):334-41. PubMed ID: 2957328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory 24-hour blood pressure monitoring: correlation between blood pressure variability and left ventricular hypertrophy in untreated hypertensive patients.
    Feola M; Boffano GM; Procopio M; Reynaud S; Allemano P; Rizzi G
    G Ital Cardiol; 1998 Jan; 28(1):38-44. PubMed ID: 9493044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study.
    Barrios V; Calderón A; Escobar C; Barrios S; Navarro-Cid J; González-Pedel V; Vegazo O; Fernandez R
    J Hypertens; 2007 Sep; 25(9):1967-73. PubMed ID: 17762663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sokolow-Lyon voltage criteria in sickle cell patients.
    Foucan L; Haddad A; Genevier I; Samuel Y; Salmi RL
    West Indian Med J; 1999 Sep; 48(3):132-6. PubMed ID: 10555459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in hypertension control and left ventricular hypertrophy over three years.
    Cuspidi C; Michey I; Meani S; Severgnini B; Fusi V; Salerno M; Valerio C; Magrini F; Zanchetti A
    Ital Heart J; 2002 Sep; 3(9):514-9. PubMed ID: 12407847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home-measured blood pressure is more strongly associated with electrocardiographic left ventricular hypertrophy than is clinic blood pressure: the Finn-HOME study.
    Niiranen TJ; Jula AM; Kantola IM; Karanko H; Reunanen A
    J Hum Hypertens; 2007 Oct; 21(10):788-94. PubMed ID: 17637793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and natural history of left ventricular hypertrophy in hypertension.
    Borhani NO
    J Clin Hypertens; 1987 Mar; 3(1):104-11. PubMed ID: 2952766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placement.
    Angeli F; Verdecchia P; Angeli E; Poeta F; Sardone M; Bentivoglio M; Prosciutti L; Cocchieri M; Zollino L; Bellomo G; Rondoni F; Garognoli O; Lenti S; Frigerio C; Gattobigio R; Benemio G; Biscottini B; Panciarola R; Buccolieri M; Liberati R; Trottini M; Cipollini F; Gemelli F; Schillaci G; Porcellati C
    J Cardiovasc Med (Hagerstown); 2006 Nov; 7(11):812-6. PubMed ID: 17060807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Left ventricular hypertrophy among hypertensive patients with diminished glomerular filtration rate].
    Grabysa R; Cholewa M
    Pol Merkur Lekarski; 2008 Oct; 25(148):309-14. PubMed ID: 19145927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol.
    Corea L; Bentivoglio M; Verdecchia P; Provvidenza M; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):365-70. PubMed ID: 6236155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
    Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B
    Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Left ventricular hypertrophy in hypertension: functional aspects].
    Lombardo M; Zaini G; Colloca W; Belli C
    G Ital Cardiol; 1987 Dec; 17(12):1039-44. PubMed ID: 2972580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arrhythmia risk and noninvasive markers in hypertensive left ventricular hypertrophy].
    Akdeniz B; Güneri S; Badak O; Aslan O; Tamci B
    Anadolu Kardiyol Derg; 2002 Jun; 2(2):121-9; AXVII. PubMed ID: 12134537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.